7 Apr 2025 • A large-scale study has highlighted the increased infection risks associated with JAK inhibitors (JAKi) compared to biologics for moderate-to-severe atopic dermatitis (AD).

JAKi treatments showed infection rates of 58.4–65.5 per 100 patient-years, significantly higher than biologics (13.6–22.0 per 100 patient-years). Treatments with abrocitinib (HR 4.1), baricitinib (HR 4.2), and upadacitinib (HR 4.0), demonstrated increased infection rates, especially herpes.

Additionally, a history of viral or fungal skin infections was found to be an independent risk factor, with hazard ratios of 1.9 for viral and 2.4 for fungal infections.

These findings underscore the importance of personalized treatment strategies, especially for patients with a history of viral or fungal skin infections.

Source: WILEY | Read Full Story